Immutep Ltd · ASX:IMM
Immutep — Prima BioMed — H1 FY2013 Earnings Presentation
10 slides from Immutep's earnings presentation, Mar 7, 2013
Slide 1: First half-year results for FY 2013
Exhibit 99.1 First half-year results for FY 2013 (period ended 31 December 2012) Supplemental Information for Prima BioMed Conference Call on March 7, 2013 ASX:PRR; NASDAQ:PBMD; ISIN:US74154B2034 1
Slide 2: Important Notice
Important Notice The purpose of the presentation is to provide an update of the business of Prima BioMed Ltd ACN 009 237 889 (ASX:PRR and NASDAQ:PBMD). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Ac
Slide 3: CVac Overview
CVac Overview Manufacturing of CVac MNCs (white blood cells) MNCs separated and matured DCs are pulsed with the Mucin-1-antigen is The DCs washed, taken from the patient by to decdritic cells (DCs) with antigen Mannan-Mucin-1 internalized by the DCs formulated, and apheresis and sent to lab growth f
Slide 4: Company strategy
Company strategy Developing personalized immunocellular therapeutics for cancer Establishment of a robust global supply, logistics, and manufacturing platform leads to clinical and commercial success Video review of Prima’s manufacturing is available at http://primabiomed.com.au/movies/movie_5.php G
Slide 5: Manufacturing development
Manufacturing development • Scaled up manufacturing of the mucin antigen (M-FP) • Achieved comparability of product manufacturing in three global facilities (Australia, USA, Germany); demonstrates our capability to transfer the technology into new facilities and it paves the way for future scale up
Slide 6: Clinical development ovarian cancer
Clinical developmentovarian – cancer • Focus of Prima’s development has been on newly diagnosed, stage III/IV, epithelial ovarian cancer patients who achieve remission after standard first-line debulking surgery and platinum/taxane chemotherapy • Significant unmet medical need and low levels of pote
Slide 7: Clinical trials ovarian cancer
Clinical trialsovarian – cancer • CAN-003: positive interim data reported in October & November 2012: – Trend of improved PFS in CVac patients – CVac induces a mucin 1 specific t cell response • CAN-003: upcoming data for all 63 patients: rd – Final immune monitoring data in 3 quarter of CY 2013 th
Slide 8: Financial results for the Half-Year ended 31 December 2012
Financial results for the Half-Year ended 31 December 2012* Loss after tax: A$ 8,030,406 Loss per basic and diluted share: 0.75 cents (A$ 0.0075 per share) Loss is down 13.78% to corresponding period last year: Loss after tax: A$ 9,314,047 Loss per basic and diluted share: 0.92 cents (A$ 0.0092 per
Slide 9: Income statement for the Half-Year ended 31 December 2012
Income statement for the Half-Year ended 31 December 2012* (unaudited) 31 December 2012 31 December 2011 A$ A$ OTHER INCOME Total other income 2,079,220 3,031,479 EXPENSES Depreciation and amortisation (118,138) (78,922) Research and development and intellectual property (7,279,338) (7,515,131) Corp
Slide 10: Exciting year ahead
Exciting year ahead • Continued scale up of manufacturing and expanding our cell collection network • Phase 2 results in ovarian cancer trial: – 3Q CY13 – immune monitoring profile – Q4 CY13 – PFS and OS data • Continued rollout of CANVAS • CVac opportunities for other cancer targets in phase 2 / PO